The Relative Strength (RS) Rating for Smith & Nephew ADR moved into a new percentile Thursday, as it got a lift from 65 to 76.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to the rest of the market.
Decades of market research reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves. See if Smith & Nephew ADR can continue to show renewed price strength and clear that threshold.
Smith & Nephew ADR is building a consolidation with a 31.72 buy point. See if the stock can break out in heavy volume.
Smith & Nephew ADR reported -2% EPS growth last quarter. Sales increased 6%. The company is expected to report its latest numbers on or around Aug. 5.
Smith & Nephew ADR earns the No. 22 rank among its peers in the Medical-Products industry group. Insulet, Boston Scientific and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
